Health Discovery of new active compounds against Alzheimer''s disease

Here is a great dementia resource for caregivers and healthcare professionals,

You will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Follow Alzheimers1 on twitter

ENEVA,(KUNA) -- Based on computer simulations, biochemists from the University of Zurich in Switzerland have shown on Tuesday shown how the active compounds and fragments of the peptide, that causes Alzheimer disease, interact with each other and found that it is the disordered structure of the peptide that determines the interactions with active compounds.
"Various molecules have been synthesized that inhibit self-assembly of the amyloid beta peptide in vitro. This peptide is strongly linked to Alzheimer's disease," said Dr. Andreas Vitalis to KUNA.
Dr. Vitalis said that more than half of all cases of dementia in the elderly can be attributed to Alzheimer's disease, adding that despite vast research efforts; an effective therapy has not been developed, and treatment consists of dealing with the symptoms.
He noted that changes in brain tissues are a hallmark of Alzheimer's. In affected individuals, small protein fragments known as amyloid beta peptides accumulate and are deposited in the gray brain matter, said Dr.Vitalis.
Researchers recently identified a series of synthetic compounds (inhibitors) that interfere with the self-assembly of the amyloid beta peptide in vitro; they influence both early stages and the transition to the characteristic amyloid fibrils.
On a theoretical level, these compounds thus satisfy an initial condition for the development of an Alzheimer drug.
In order to understand the interactions between the amyloid beta peptide and active compounds at a structural level, Marino Convertino, Andreas Vitalis, and Amedeo Caflisch from the University of Zurich's Department of Biochemistry simulated these interactions on the computer.
"In doing so, we focused on a fragment of the peptide that is thought to control both interactions with inhibitors and progression of disease," Dr.
Vitalis explained to KUNA.
Based on these simulations, the biochemists were able to identify a hierarchy of interaction patterns between the peptide and various active compounds. To their surprise, they discovered that the disordered structure of the peptide controls the interactions.
"The peptide's disorder and flexibility enable it to adapt to many basic structural frameworks," Dr.Vitalis explained.
Often it is only subparts of the molecules that mediate interactions on the compound side. However, even minimal changes to a compound may induce measurable changes to the peptide-compound interactions.
"Design of active compounds that influence the amyloid beta peptide structurally in a specific manner will only be possible with the aid of high-resolution methods that are limited to one or a few molecules," concludes Vitalis.
In the next step, the researchers from the University of Zurich want to identify new classes of active substances with controllable properties that interact with the amyloid beta peptide